"Recent Study Findings Represent "Watershed Moment" in Metastatic Bladder Cancer"
After showing promise in a phase 2 study, the FDA granted atezolizumab priority review for patients with certain locally advanced or metastatic urothelial cancer. Study author Matthew Galsky, MD, study author and director of genitourinary medical oncology at the Icahn School of Medicine at Mount Sinai, says the IMvigor findings represent a “watershed moment” for the treatment of metastatic urothelial carcinoma. “We really have not had a lot of good treatments for patients in this disease state, ever,” says Dr. Galsky. “Once patients progress on standard first-line chemotherapy, we really have very little to offer them. Atezolizumab could potentially be the first drug approved in this space.” Learn more.
AI-Driven Study Redefines Right Heart Health Assessment With Novel Predictive Model
Jan 04, 2024 View All Press Releases
Demystifying a Key Receptor in Substance Use and Neuropsychiatric Disorders
Jan 02, 2024 View All Press Releases